H&Q HEALTHCARE INVESTORS Form N-Q March 02, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0578
Expires: April 30, 2010

Estimated average burden hours per

response.....10.5

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number

811-04889

H&Q Healthcare Investors (Exact name of registrant as specified in charter)

2 Liberty Square, 9th Floor, Boston, MA (Address of principal executive offices)

02109 (Zip code)

(Name and address of agent for service)

Registrant s telephone number, including area code: 617-772-8500

Date of fiscal year end: September 30

Date of reporting period: 12/31/08

Item 1. Schedule of Investments.

H&O HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

DECEMBER 31, 2008

(Unaudited)

CONVERTIBLE SECURITIES AND WARRANTS 11.7% of Net Assets

SHARES		VALUE	
	Convertible Preferred (Restricted)(a) 11.7%		
	Drug Discovery Technologies 1.5%		
2,380,953	Agilix Corporation Series B (b) (c)	\$	141,809
375,000	Ceres, Inc. Series C (b)		2,437,500
32,193	Ceres, Inc. Series C-1 (b)		209,255
280,105	Ceres, Inc. Series D (b)		1,820,683
40,846	Ceres, Inc. Series F (b)		265,499
8,170	Ceres, Inc. warrants (expiration 9/05/15) (b)		0
300,000	Zyomyx, Inc. Series A New (b)		30,000
300	Zyomyx, Inc. Series B New (b)		30
	Emerging Biopharmaceuticals 0.8%		
306,413	MacroGenics, Inc. Series D (b)		199,812
75,217	MacroGenics, Inc. Series D (b)		32,697
2,123,077	TargeGen, Inc. Series C (b)		1,840,007
586,871	TargeGen, Inc. Series D (b)		508,624
	Healthcare Services 1.6%		
5,384,615	PHT Corporation Series D (b) (c)		4,200,000
1,204,495	PHT Corporation Series E (b) (c)		939,506
149,183	PHT Corporation Series F (b) (c)		116,363
	Medical Devices and Diagnostics 7.8%		
3,424,756	CardioKinetix, Inc. Series C (b) (c)		2,359,999
4,852,940	Concentric Medical, Inc. Series B (b) (c)		4,852,940
1,744,186	Concentric Medical, Inc. Series C (b) (c)		1,744,186
683,000	Concentric Medical, Inc. Series D (b) (c)		683,000
652,013	Concentric Medical, Inc. Series E (b) (c)		652,013
1,724,230	Elemé Medical, Inc. Series C (b) (c)		2,596,001
222,222	EPR, Inc. Series A (b)		2,222
2,292,152	FlowCardia, Inc. Series C (b)		2,458,333
3,669,024	Labcyte Inc. Series C (b)		1,920,000
2,950,000	Magellan Biosciences, Inc. Series A (b)		2,950,000
1,547,988	OmniSonics Medical Technologies, Inc. Series A-1 (b)		356,036
1,263,099	OmniSonics Medical Technologies, Inc. Series B-1 (b)		290,512
65,217	TherOx, Inc. Series H (b)		416,085
149,469	TherOx, Inc. Series I (b)		953,612
4,220	TherOx, Inc. warrants (expiration 1/26/10) (b)		0
8,141	TherOx, Inc. warrants (expiration 6/09/09) (b)		0
921,875	Xoft, Inc. Series D (b)		3,079,063
176,647	Xoft, Inc. Series E (b)		590,001
	TOTAL CONVERTIBLE SECURITIES AND WARRANTS		
	(Cost \$46,775,337)	\$	38,645,788

SHARES		VALUE	
	COMMON STOCKS AND WARRANTS 77.6%		
	Biopharmaceuticals 34.4%		
1,033,968	Akorn, Inc. (b)	\$	2,378,126
202,223	Akorn, Inc. warrants (expiration 3/08/11) (a) (b)		28,311
163,146	Alexion Pharmaceuticals, Inc. (b)		5,904,254
260,793	Amgen Inc. (b)		15,060,796
80,000	Amylin Pharmaceuticals, Inc. (b)		868,000
756,876	Antisoma Plc (b) (d)		255,727
4,624,175	Antisoma Plc 12 Month Lock-up (Restricted) (a) (b) (d)		1,328,020
513,798	Antisoma Plc 18 Month Lock-up (Restricted) (a) (b) (d)		138,878
213,120	Biogen Idec Inc. (b)		10,150,906
127,450	Forest Laboratories, Inc. (b)		3,246,151
128,830	Genentech, Inc. (b)		10,681,295
207,018	Genzyme Corporation (b)		13,739,785
424,040	Gilead Sciences, Inc. (b)		21,685,406
262,804	Hologic, Inc. (b)		3,434,848
12,785	Intuitive Surgical, Inc. (b)		1,623,567
247,845	Martek Biosciences Corporation		7,512,182
92,205	Myriad Genetics, Inc. (b) (e)		6,109,503
226,500	Vertex Pharmaceuticals Inc. (b) (e)		6,881,070
147,689	XenoPort, Inc. (b)		3,704,040
		1	14,730,865
	Biotechnology 1.9%		
472,000	Athersys, Inc. (b)		212,447
118,000	Athersys, Inc. warrants (expiration 6/08/12) (a) (b)		0
180,783	Life Technologies Corporation (b)		4,214,052
177,766	Momenta Pharmaceuticals, Inc. (b)		2,062,086
	D D 11 A 24		6,488,585
225 450	Drug Delivery 3.7%		2 10 - 2 12
327,450	Alkermes, Inc. (b)		3,487,342
314,000	CVS Caremark Corporation		9,024,360
	D D' T 1 1 ' 0.50		12,511,702
242 422	Drug Discovery Technologies 9.7%		70.020
243,433	Avalon Pharmaceuticals, Inc. (b)		70,839
288,280	Celgene Corporation (b)		15,936,119
38,669	Cephalon, Inc. (b)		2,979,060
123,508 113,400	Cougar Biotechnology, Inc. (b) OSI Pharmaceuticals, Inc. (b)		3,211,208 4,428,270
574,211	Penwest Pharmaceuticals Co. (b) Penwest Pharmaceuticals Co. warrants (expiration 2/11/12) (a) (b)		901,511
287,106 72,800	Penwest Pharmaceuticals Co. warrants (expiration 3/11/13) (a) (b) United Therapeutics Corporation (b)		160,779 4,553,640
300,000	Zyomyx, Inc. (Restricted) (a) (b)		3,000
300,000	Zyomya, mc. (restricted) (a) (b)		32,244,426
			32,244,420

SHARES		VALUE	
	Emerging Biopharmaceuticals 1.2%		
621,473	ACADIA Pharmaceuticals Inc. (b)	\$	559,326
170,698	DOV Pharmaceutical, Inc. warrants (expiration 12/31/09) (a) (b)		0
650,550	Exelixis, Inc. (b)		3,265,761
454,078	NitroMed, Inc. (b)		163,468
			3,988,555
	Generic Pharmaceuticals 7.6%		
144,519	Illumina, Inc. (b)		3,764,720
353,100	Mylan Inc. (b)		3,492,159
127,369	Perrigo Company		4,115,292
332,496	Teva Pharmaceutical Industries, Ltd. (f)		14,154,350
			25,526,521
	Healthcare Services 10.3%		
67,700	Aetna Inc.		1,929,450
222,222	Aveta, Inc. (Restricted) (a) (b)		2,222,220
520,460	CardioNet, Inc. (b)		12,829,339
134,660	Catalyst Health Solutions, Inc. (b)		3,278,971
137,920	ICON Plc (b) (f)		2,715,645
130,385	Medco Health Solutions, Inc. (b)		5,464,435
122,700	Pharmaceutical Product Development, Inc.		3,559,527
306,208	Syntiro Healthcare Services (Restricted) (a) (b)		306
59,050	WellPoint, Inc. (b)		2,487,777
			34,487,670
	Medical Devices and Diagnostics 8.8%		
473,430	Align Technology, Inc. (b)		4,142,513
159,854	IDEXX Laboratories, Inc. (b)		5,767,532
225,107	Inverness Medical Innovations, Inc. (b)		4,256,773
84,750	Laboratory Corporation of America Holdings (b)		5,458,748
97,400	Masimo Corporation (b)		2,905,442
160,000	Masimo Laboratories, Inc. (Restricted) (a) (b)		56,460
830,292	Medwave, Inc. (b) (c)		415
207,573	Medwave, Inc. warrants (expiration 8/21/11) (a) (b) (c)		0
93,008	OmniSonics Medical Technologies, Inc. (Restricted) (a) (b)		930
125,000	PerkinElmer, Inc.		1,738,750
56,500	Phase Forward Inc. (b)		707,380
208	Songbird Hearing, Inc. (Restricted) (a) (b)		139
106,575	Stryker Corporation		4,257,671
			29,292,753
	TOTAL COMMON STOCKS AND WARRANTS		
	(Cost \$289,540,419)	\$	259,271,077
	, , ,		, , ,

PRI	NCIPAL			
AM	OUNT		VALUE	
		SHORT-TERM INVESTMENTS 10.1%		
\$	5,692,000	American Express Corporation; 0.01% due 01/02/09	\$	5,691,999
	28,171,000	Repurchase Agreement, State Street Bank and Trust Co., repurchase value \$28,171,016		
		(collateralized by U.S. Treasury Bill 0.26% discount, 07/02/09, market value \$28,737,592);		
		0.01% due 01/02/09		28,171,000
		TOTAL SHORT-TERM INVESTMENTS		
		(Cost \$33,862,999)	\$	33,862,999
		TOTAL INVESTMENTS 99.4%		
		(Cost \$370,178,755`)	\$	331,779,864
		OTHER ASSETS IN EXCESS OF LIABILITIES 0.6%		2,166,216
		NET ASSETS - 100%	\$	333,946,080
		NET ASSETS - 100%	\$	333,946,080

⁽a) Security fair valued.

SCHEDULE OF WRITTEN OPTIONS

CONTRACTS (100 SHARES EACH)		EXPIRATION DATE	CURRENT VALUE	
	CALL OPTIONS WRITTEN			
89	Myriad Genetics, Inc., strike @ 70	Feb - 2009	\$	(29,993)
295	Vertex Pharmaceuticals, Inc., strike @ 35	Feb - 2009		(38,940)
	TOTAL CALL OPTIONS WRITTEN			
	(Premium received \$68,933)		\$	(68,933)
	4			

⁽b) Non-income producing security.

⁽c) Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of \$18,286,232).

⁽d) Foreign security.

⁽e) A portion of security is pledged as collateral for call options written.

⁽f) American Depository Receipt.

H&O HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

DECEMBER 31, 2008

(Unaudited)

(Continued)

The Fund adopted Financial Accounting Standards Board Statement of Financial Accounting Standards No. 157, Fair Value Measurements (FAS 157), effective October 1, 2008. In accordance with FAS 157, fair value is defined as the price that the Fund would receive upon selling an investment in a timely transaction to an independent buyer in the principal or most advantageous market for the investment. FAS 157 established a three-tier hierarchy that prioritizes the inputs to valuation techniques giving the highest priority to readily available unadjusted quoted prices in active markets (Level I inputs) and the lowest priority to unobservable inputs (Level 3 inputs) when market prices are not readily available or reliable. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability and may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity s own assumptions about the factors market participants would use in pricing the asset or liability, and would be based on the best information available.

The three-tier hierarchy of inputs is summarized in the three broad levels listed below.

- Level 1 quoted prices in active markets for identical investments
- Level 2 prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)
- Level 3 prices determined using significant unobservable inputs (including the Fund s own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used as of December 31, 2008 in valuing the Fund s investments carried at value:

Valuation Inputs	estments in Securities
Level 1 - Quoted Prices in Active Markets	\$ 289,195,033
Level 2 - Other Significant Observable Inputs	
Level 3 - Significant Unobservable Inputs	42,584,831
Balance as of December 31, 2008	\$ 331,779,864

Securities valuation policies and other investment related disclosures are hereby incorporated by reference to the Fund $\,$ s most recent annual report previously filed with the Securities and Exchange Commission on Form N-CSR.

Following is a reconciliation of investments in which significant unobservable inputs (Level 3) were used in determining value:

Valuation Inputs	1	nvestments in Securities
Balance as of 09/30/08	\$	59,245,578
Accrued discounts/premiums		
Realized gain/loss and change in unrealized		
appreciation/depreciation		(4,913,401)
Net purchases/sales		(55,733)
Net transfers in and/or out of Level 3		(11,691,613)
Balance, as of 12/31/08	\$	42,584,831
Net change in unrealized appreciation/depreciation		
from investments still held as of 12/31/08	\$	(3,238,533)

Investment Valuation - Investments traded on national securities exchanges or in the over-the-counter market that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between the last bid and asked prices. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more dealers that make markets in the securities. Publicly traded investments for which market quotations are not readily available or whose quoted price may otherwise not reflect fair value and the fair value of venture capital and other restricted securities are valued in good faith by the Adviser pursuant to valuation policies and procedures approved by the Trustees. Such values are subject to oversight and ratification by the Trustees. However, because of the uncertainty of fair valuations, these estimated values may differ significantly from the values that would have been used had a ready market for these securities existed, and the differences could be material. Each such fair value determination is based on a consideration of relevant factors. Factors the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the issuer which may include an analysis of the company s financial statements, the company s products or intended markets or the company s technologies; and (iii) the price of a security negotiated at arm s length in an issuer s completed subsequent round of financing. Short-term investments with maturity of 60 days or less are valued at amortized cost.

Venture Capital and Other Restricted Securities - The Fund may invest in venture capital and other restricted securities if these securities would currently comprise 40% or less of net assets. The value of these securities represents 13% of the Fund s net assets at December 31, 2008. The following table details the acquisition date, cost, carrying value per unit, and value of the Fund s venture capital and other restricted securities at December 31, 2008. The Fund on its own does not have the right to demand that such securities be registered.

6

Coursily (g)		Agguigition		Carrying Value		
Agils Corporation 11/800 Is 2,495,500 S 0.00 S 141,800 141,800 Antisoma Ple (h) 11/800 Is 2,495,500 S 0.00 S 1,328,000 18 Month Lock-up Restricted Common 12/5/03 - 6/11/08 S 36,343 S 0.27 S 138,878 3.027 S 138,878 Aveta, Inc.	Security (g)		Cost		Value	
Series B Cvt. Pfd. 11801 \$ 2,495.00 \$ 0.00 \$ 141809 128003 - 601108 \$ 4,827,086 \$ 0.29 \$ 1,328,020 \$ 1800000 \$ 18000000 \$ 128003 - 601108 \$ 36,343 \$ 0.27 \$ 138,878 \$ 0.27 \$ 138,878 \$ 0.28 \$ 138,000000000000000000000000000000000000				P		
Antisoma Pic (h) 2 Month Lock-up Restricted Common 12/5/03 - 6/11/08 536,343 0.27 138,878 Aveta, Inc. Restricted Common 12/5/03 - 6/11/08 536,343 0.27 138,878 Aveta, Inc. Restricted Common 12/21/05 3,004,731 10,00 2,222,220 CardioKinetix, Inc. Series C Cvt. Pfd. Series C Cvt. Pfd. Series C Cvt. Pfd. 12/23/08 Series C Cvt. Pfd. Series C Cvt. Pfd. Series C Cvt. Pfd. 3/14/01 11,1508 6.50 24,375,905 Series D Cvt. Pfd. 3/14/01 11,1508 6.50 24,375,905 Series D Cvt. Pfd. 3/14/01 11,1508 6.50 26,379 Restricted Common Concentric Medical, Inc. Series C Cvt. Pfd. 3/14/01 12/18/03 Series P C Vt. Pfd. 3/14/04 Series C Cvt. Pfd. 3/15/08 Series D Cvt. Pfd. 3/15/08 Ser		11/8/01	\$ 2,495,500	\$ 0.06	\$ 141,809	
IS Month Lock-up Restricted Common 125/03 - 6/11/08 536,343 0.27 138,878 Aveta, Inc.	Antisoma Plc (h)					
Aveta. Inc. Restricted Common 12/21/05 3,004,731 10.00 2,222/20 Cardio Kinetx, Inc. Series C CVt. Pfd. 5/22/08 2,367,320 0.69 2,359,999 Ceres, Inc.		12/5/03 - 6/11/08	4,827,086	0.29	1,328,020	
Restricted Common 12/21/05 3,004,731 10.00 2,222,220 Cardio Kinetis, Inc. Series C Cxt. Pfd. \$5/22/08 2,367,320 0.69 2,359,999 Ceres, Inc. Series C Cxt. Pfd. 12/23/98 1,502,732 6.50 2,437,500 Series C Cxt. Pfd. 3/31/01 111,508 6.50 2,827,500 Series D Cxt. Pfd. 3/14/01 1,608,294 6.50 1,820,068 Series P Cvt. Pfd. 9/5077 20 0.00 0 0 Series P Cvt. Pfd. 5/702,1/24/03 3,330,988 1.00 4,852,940 0 <td< td=""><td>18 Month Lock-up Restricted Common</td><td>12/5/03 - 6/11/08</td><td>536,343</td><td>0.27</td><td>138,878</td></td<>	18 Month Lock-up Restricted Common	12/5/03 - 6/11/08	536,343	0.27	138,878	
CardioKinetix, Inc. Scries C Cvt. Pfd. \$0,2208 \$2,367,320 \$0,69 \$2,359,999 \$0,000 \$0,0	Aveta, Inc.					
Series C Cv. Pfd. \$52,008 2,367,320 0.69 2,359,999 Ceres, Inc. Series C Cvt. Pfd. 1,202,398 1,502,732 6,50 2,437,500 Series C C Vt. Pfd. 371,401 111,508 6,50 1,820,683 Series D C Vt. Pfd. 391,401 1,668,294 6,50 1,820,683 Series F C Vt. Pfd. 975,007 20 0,00 0 205,499 Warrants (explaration 90/5/15) 975,007 0 0,00 0 0 Concentric Medical, Inc. 577/02,1/24/03 3,330,988 1,00 4,852,940 Series C C Vt. Pfd. 9/30/05 958,007 1,00 633,000 Series C C Vt. Pfd. 9/30/05 958,007 1,00 633,000 Series C C Vt. Pfd. 9/30/05 958,007 1,00 633,000 Series C C Vt. Pfd. 9/30/05 958,007 1,00 652,013 Ellemé Medical, Inc. 12/18/08 3,252,672 1,51 2,596,001 Eries C Vt. Pfd. 3/99/4 1,000,409 0,01 </td <td>Restricted Common</td> <td>12/21/05</td> <td>3,004,731</td> <td>10.00</td> <td>2,222,220</td>	Restricted Common	12/21/05	3,004,731	10.00	2,222,220	
Ceres, Inc. Series C CVt. Pfd. 1.20,2308 1.502,732 6.50 2.437,500 Series C C Vt. Pfd. 3/31,001 111,508 6.50 209,255 Series D C Vt. Pfd. 3/14,001 1.668,294 6.50 205,499 Warrants (expiration 905/15) 9/5077 268,136 6.50 205,499 Warrants (expiration 905/15) 9/5077 200 0.00 0.00 205,499 Warrants (expiration 905/15) 9/5077 200,500 1.00 48,559,490 1.00 48,559,490 1.00 68,300 1.00 68,300 1.00 68,300 1.00 68,300 1.00 65,2013 1.20,800 1.00 20,200 1.00 22,20 <td< td=""><td>CardioKinetix, Inc.</td><td></td><td></td><td></td><td></td></td<>	CardioKinetix, Inc.					
Series C C CVL Přd. 1,202,398 1,502,732 6,50 2,437,500 Series C I CVL Přd. 3/31/01 111,508 6,50 209,255 Series D CVL Přd. 3/14/01 1,668,294 6,50 1,820,683 Series P CVL Přd. 9/50/07 20 0.00 0 Concentric Medical, Inc. 8 7/702,1/24/03 3,330,988 1.00 4,852,940 Series C CVL Přd. 12/19/03 1,500,818 1.00 1,744,186 Series C CVL Přd. 9/30/05 98,807 1.00 683,000 Series C CVL Přd. 12/19/03 1,500,818 1.00 1,744,186 Series C CVL Přd. 9/30/05 98,807 1.00 683,000 Series C CVL Přd. 7/15/08 3,25,672 1.51 2,596,001 Elemé Medical, Inc. 7/15/08 3,25,672 1.51 2,596,001 Elemé Medical, Inc. 3/99/4 1,000,409 0.01 2,222 FlowCardia, Inc. 2 1,000,409 0.01 2,259,000 Eries C	Series C Cvt. Pfd.	5/22/08	2,367,320	0.69	2,359,999	
Series C-I CVt, Pfd. 3/31/01 111.508 6.50 209,255 Series D CVt, Pfd. 3/14/01 1.668.294 6.50 1.820.683 Series P CVt, Pfd. 9/5/07 208,136 6.50 265,898 Warrants (expiration 9/05/15) 9/5/07 0 0.00 0 Concentric Medical, Inc. 5/7/02,1/24/03 3.330.988 1.00 4.852,440 Series C CVt, Pfd. 12/19/03 1.500.818 1.00 1.744,186 Series C CVt, Pfd. 12/19/03 1.500.818 1.00 1.744,186 Series C CVt, Pfd. 12/18/08 653,960 1.00 683,000 Series C CVt, Pfd. 7/15/08 3.252,672 1.51 2.596,001 Eries C CVt, Pfd. 3/99/4 1,000,409 0.01 2.222 FlowCardia, Inc. 2 2 1.51 2.596,001 Series C CVt, Pfd. 8/29/07 2,474,768 1.07 2,458,333 Series C Cvt, Pfd. 9/408 1,002,546 0.65 199,812 Series C Cvt, Pfd. <td>Ceres, Inc.</td> <td></td> <td></td> <td></td> <td></td>	Ceres, Inc.					
Series D Cvt. Ptd. 3/14/01 1,668,294 6,50 1,820,683 Series F Cvt. Ptd. 9/5/07 268,136 6,50 265,499 Warrants (expiration 9/05/15) 9/5/07 0 0.00 0 Concentric Medical, Inc. 5/7/02,1/24/03 3,330,988 1.00 4,852,940 Series D CV, Ptd. 12/19/03 1,500,818 1.00 1,744,186 Series D CV, Ptd. 9/30/05 98,8007 1.00 683,000 Series C V, Ptd. 12/18/08 653,960 1.00 652,013 Elemé Medical, Inc. 5/7/15/08 3,252,672 1.51 2,596,001 EPR, Inc. 3/9/94 1,000,409 0.01 2,222 FlowCardia, Inc. 3/9/94 1,000,409 0.01 2,259,000 EPR, Inc. 3/9/94 1,000,409 0.01 2,259,000 EPR, Inc. 3/9/97 2,474,768 1.07 2,458,333 Laboration Inc. 3/9/97 2,474,768 1.07 2,458,333 Erries C V. Ptd. 9/1/805						
Series F Cvt. Ptd. 9/5/07 268,136 6.50 265,499 Warrants (expiration 9/05/15) 9/5/07 0 0.00 0 Concentric Medical, Inc. 57/102, 17/24/03 3,330,988 1.00 4,852,940 Series B Cvt. Ptd. 12/19/03 1,500,818 1.00 1,744,186 Series D Cvt. Ptd. 9/30/05 958,007 1.00 683,000 Series E Cvt. Ptd. 12/18/08 653,960 1.00 683,000 Series E C Vt. Ptd. 7/15/08 3,252,672 1.51 2,596,001 Elemé Medical, Inc. 3/9/94 1,000,409 0.01 2,259,001 Series C C Vt. Ptd. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 7/18/05 1,924,893 0.52 1,920,000 Macrogenics, Inc. 1,924,893 0.52 1,920,000 Macrogenics, Inc. 1,924,893 1.02 2,950,000 Mayellan Biosciences, Inc. 1,924,893						
Warrants (expiration 9/05/15) 9/5/07 0 0.00 0 Concentric Medical, Inc. Series B Cvt. Pfd. 577/02, 1/24/03 3,330,988 1.00 4,852,940 Series B Cvt. Pfd. 12/119/03 1,500,818 1.00 1,744,186 Series D Cvt. Pfd. 9/30/05 958,007 1.00 683,000 Series C Vt. Pfd. 12/18/08 653,960 1.00 652,013 Elemé Medical, Inc. 7/15/08 3,252,672 1.51 2,596,001 EPR, Inc. 8/29/07 2,474,768 1.07 2,458,333 Series C Vt. Pfd. 8/29/07 2,474,768 1.07 2,458,333 Labcyte Inc. 8/29/07 2,474,4768 1.07 2,458,333 Labcyte Inc. 8/29/07 2,474,4768 1.07 2,458,333 Labcyte Inc. 8/29/07 2,474,4768 1.07 2,458,333 Labcyte Inc. 9/40/08 1,002,469 0.65 199,812 Series C Cvt. Pfd. 9/40/08 1,002,469 0.65 199,812	Series D Cvt. Pfd.					
Concentric Medical, Inc. Series B Cvt. Pfd. 577/02, 1/24/03 3,330,988 1.00 4,852,940 Series C Cvt. Pfd. 12/19/03 1,500,818 1.00 1,744,186 Series D Cvt. Pfd. 9/30/05 958,007 1.00 683,000 Series E C Vt. Pfd. 12/18/08 653,960 1.00 652,013 Elemé Medical, Inc. 3/15/08 3,252,672 1.51 2,596,001 Series C Cvt. Pfd. 3/9/04 1,000,409 0.01 2,222 FlowCardia, Inc. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 8/29/07 2,474,768 1.07 2,458,333 Eeries C Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D C Vt. Pfd. 9/4/08 1,002,546 0.65 199,812						
Series B Cvt. Pfd. 57/02, 1/24/03 3,330,988 1.00 4,852,940 Series C Cvt. Pfd. 12/19/03 1,500,818 1.00 1,744,186 Series D Cvt. Pfd. 9/30/05 958,007 1.00 683,000 Series C Cvt. Pfd. 12/18/08 653,960 1.00 652,013 Elemé Medical, Inc. 8/15/08 3,252,672 1.51 2,596,001 EPR, Inc. 3/9/94 1,000,409 0.01 2,222 FlowCardia, Inc. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 8/29/07 1,924,893 0.52 1,920,000 MacroGenics, Inc. 1,94/08 1,002,546 0.65 199,812 Series C Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd.		9/5/07	0	0.00	0	
Series C Cvt. Pfd. 12/19/03 1,500,818 1,00 1,744,186 Series D Cvt. Pfd. 9/30/05 958,007 1.00 683,000 Series C Cvt. Pfd. 12/18/08 653,960 1.00 652,013 Elemé Medical, Inc. 3/15/08 3,252,672 1.51 2,596,001 EPR, Inc. 3/9/94 1,000,409 0.01 2,222 FlowCardia, Inc. 8/29/07 2,474,768 1.07 2,458,333 Labcyte Inc. 8/29/07 1,924,893 0.52 1,920,000 MacroGenics, Inc. 7/18/05 1,924,893 0.52 1,920,000 MacroGenics, Inc. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. 11/28/06 2,954,179 1.00 2,950,000 Masimo L						
Series D Cvt. Pfd. 9/30/05 958,007 1.00 683,000 Series E Cvt. Pfd. 12/18/08 653,960 1.00 652,013 Elemé Medical, Inc. Series C Cvt. Pfd. 7/15/08 3,252,672 1.51 2,596,001 EPR, Inc. Series C Vvt. Pfd. 3/9/94 1,000,409 0.01 2,222 FlowCardia, Inc. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. 8/29/07 1,924,893 0.52 1,920,000 MacroGenics, Inc. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. 10/10/10/10/10/10/10/10/10/10/10/10/10/1					, ,	
Series E Cvt. Pfd. 12/18/08 653,960 1.00 652,013 Eleme Medical, Inc. Series C Vct. Pfd. 7/15/08 3,252,672 1.51 2,596,001 EPR Inc. Series A Cvt. Pfd. 3/9/94 1,000,409 0.01 2,222 How Cardia, Inc. Series C Cvt. Pfd. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. Series C Cvt. Pfd. 7/18/05 1,924,893 0.52 1,920,000 Macrogenics, Inc. Series D Cvt. Pfd. 9/4/08 315,748 0.43 3,26,97 Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimus Laboratorics, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimus Laboratorics, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Series A C						
Page			,			
Series C Cvt. Pfd. 7/15/08 3,252,672 1.51 2,596,001 EPR. Inc. 3/9/94 1,000,409 0.01 2,222 FlowCardia, Inc. Series C Cvt. Pfd. 8/29/07 2,474,768 1.07 2,458,333 Labcyte Inc. Series C Cvt. Pfd. 7/18/05 1,924,893 0.52 1,920,000 MacroGenics, Inc. Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 267 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Restricted Common 3/31/98 0 0.35 56,460 Restricted Common Sedicial Technologies, Inc. Series A L Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series A L Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Series A L Cvt. Pfd. 7/23/01 4,20		12/18/08	653,960	1.00	652,013	
EPR, Inc. Series A Cvt. Pfd. 3/9/94 1,000,409 0.01 2,222 FlowCardia, Inc. Series C Cvt. Pfd. 8/29/07 2,474,768 1.07 2,458,333 Labeyte Inc. Series C Cvt. Pfd. 7/18/05 1,924,893 0.52 1,920,000 MacroGenics, Inc. Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. 9/4/08 315,748 0.43 32,697 Magillan Biosciences, Inc. 8 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. 8 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. 8 1 0.03 356,060 Restricted Common 3/31/98 0 0.35 56,460 OmniSonics Medical Technologies, Inc. 8 10/1/03 1,800,514 0.23 356,036 Series A I Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 295,	,					
Series A Cvt. Pfd. 3/9/94 1,000,409 0.01 2,222 FlowCardia, Inc. 8/29/07 2,474,768 1.07 2,458,333 Labcyte Inc. 8/29/07 2,474,768 1.07 2,458,333 Labcyte Inc. 7/18/05 1,924,893 0.52 1,920,000 MacroGenics, Inc. 8/29/07 8/24,893 0.65 199,812 Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellam Biosciences, Inc. 8/24/01 8/25/47 1.00 2,950,000 Masimo Laboratories, Inc. 8/25/47 1.00 2,950,000 Masimo Laboratories, Inc. 8/25/47 1.00 2,950,000 Masimo Laboratories, Inc. 8/25/47 1.00 0.035 56,460 OmniSonies Medical Technologies, Inc. 8/25/47 1.00 0.35 56,460 OmniSonies Medical Technologies, Inc. 8/25/25 8/25/25 0.23 390,512 8 826,036 890,512 <td></td> <td>7/15/08</td> <td>3,252,672</td> <td>1.51</td> <td>2,596,001</td>		7/15/08	3,252,672	1.51	2,596,001	
FlowCardia, Inc. Series C Cvt. Pfd. 8/29/07 2,474,768 1.07 2,458,333 2.65 2.6						
Series C Cvt. Pfd. 8/29/07 2,474,768 1.07 2,458,333 Labcyte Inc. Series C Cvt. Pfd. 7/18/05 1,924,893 0.52 1,920,000 MacroGenics, Inc. Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Series A Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Restricted Common 3/31/98 0 0.35 56,460 OmniSonics Medical Technologies, Inc. Series A -1 Cvt. Pfd. 0.10/103 1,800,514 0.23 356,036 Series A -1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 299,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation 912/03 - 10/14/04 <td< td=""><td></td><td>3/9/94</td><td>1,000,409</td><td>0.01</td><td>2,222</td></td<>		3/9/94	1,000,409	0.01	2,222	
Labcyte Inc. Series C Cvt. Pfd. 7/18/05 1,924,893 0.52 1,920,000 MacroGenics, Inc. Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Series A Cvt. Pfd. 10/103 1,800,514 0.23 356,036 Series A-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Series B-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation 7/23/01 4,205,754 0.78 4,200,000 Series D Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 193,506 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>						
Series C Cvt. Pfd. 7/18/05 1,924,893 0.52 1,920,000 MacroGenics, Inc. Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Series A Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Mestricted Common 3/31/98 0 0.35 56,460 OmiSonics Medical Technologies, Inc. Series A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series A-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation 7/23/01 4,205,754 0.78 4,200,000 Series D Cvt. Pfd. 9/12/03 - 10/14/04 941,669		8/29/07	2,474,768	1.07	2,458,333	
MacroGenics, Inc. Series D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Series A Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 OmniSonies Medical Technologies, Inc. Series A I Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series B -1 Cvt. Pfd. 6/4/07, 1/1/5/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 9,30,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 9,30,00 Series F Cvt. Pfd. 9/12/03 - 10/14/00 3,004,861 0.67 139 <	•	= 14 0 10 F	4.004.000	0.70	4.020.000	
Scries D Cvt. Pfd. 9/4/08 1,002,546 0.65 199,812 Scries D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. Scries A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Restricted Common 3/31/98 0 0.35 56,460 OmniSonics Medical Technologies, Inc. Scries A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Scries A-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Scries D Cvt. Pfd. 0.723/01 4,205,754 0.78 4,200,000 Scries E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Scries F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services R		7/18/05	1,924,893	0.52	1,920,000	
Series D Cvt. Pfd. 9/4/08 315,748 0.43 32,697 Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Restricted Common 3/31/98 0 0.35 56,460 OmniSonics Medical Technologies, Inc. Series A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series B-1 Cvt. Pfd. 6/4/07,11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01,7/2/07 2,409,033 0.01 930 PHT Corporation Series B-1 Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series D Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntro Healthcare Services Restricted Common 12/14/00 3,004,861 0.67 139	•	0.14.00	1,000,546	0.65	100.012	
Magellan Biosciences, Inc. Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. 8 0 0.35 56,460 Restricted Common 3/31/98 0 0.35 56,460 OmniSonics Medical Technologies, Inc. 8 0 0.35 56,460 Series A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series B-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation 7/23/01 4,205,754 0.78 4,200,000 Series D Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 9/12/03 - 10/14/08 122,580 0.78 116,363 Songbird Hearing, Inc. 8 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services 8 8 2,759,79 1,200,325 0.001 306 TargeGen, Inc. 8						
Series A Cvt. Pfd. 11/28/06 2,954,179 1.00 2,950,000 Masimo Laboratories, Inc. Restricted Common 3/31/98 0 0.35 56,460 OmniSonics Medical Technologies, Inc. Series A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series B-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series D Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 0.78 116,363 Songbird Hearing, Inc. Res		9/4/08	315,/48	0.43	32,697	
Masimo Laboratories, Inc. Restricted Common 3/31/98 0 0.35 56,460 OrmiSonics Medical Technologies, Inc. Series A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series B-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624		11/20/06	2.054.170	1.00	2.050.000	
Restricted Common 3/31/98 0 0.35 56,460 OmniSonics Medical Technologies, Inc. 10/1/03 1,800,514 0.23 356,036 Series A-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Series B-1 Cvt. Pfd. 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOX, Inc. Series H Cvt. Pfd. 9/11/00 3,002		11/28/00	2,934,179	1.00	2,930,000	
OmniSonics Medical Technologies, Inc. Series A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series B-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085		2/21/09	0	0.25	56 160	
Series A-1 Cvt. Pfd. 10/1/03 1,800,514 0.23 356,036 Series B-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd.		3/31/98	U	0.55	30,400	
Series B-1 Cvt. Pfd. 6/4/07, 11/15/07 960,516 0.23 290,512 Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. 8 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services 8 8 1,200,325 0.001 306 TargeGen, Inc. 2/5/97 1,200,325 0.001 306 TargeGen, Inc. 8/30/05 2,763,495 0.87 1,840,007 Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958<	C .	10/1/03	1 200 514	0.23	356.036	
Restricted Common 5/24/01, 7/2/07 2,409,033 0.01 930 PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 <						
PHT Corporation Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0						
Series D Cvt. Pfd. 7/23/01 4,205,754 0.78 4,200,000 Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		3/24/01, //2/07	2,409,033	0.01	930	
Series E Cvt. Pfd. 9/12/03 - 10/14/04 941,669 0.78 939,506 Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		7/23/01	4 205 754	0.78	4 200 000	
Series F Cvt. Pfd. 7/21/08 122,580 0.78 116,363 Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0						
Songbird Hearing, Inc. Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0						
Restricted Common 12/14/00 3,004,861 0.67 139 Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		7721700	122,000	0170	110,000	
Syntiro Healthcare Services Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0	0	12/14/00	3.004.861	0.67	139	
Restricted Common 2/5/97 1,200,325 0.001 306 TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0			2,001,002			
TargeGen, Inc. Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		2/5/97	1.200.325	0.001	306	
Series C Cvt. Pfd. 8/30/05 2,763,495 0.87 1,840,007 Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		_,,,,	-,,			
Series D Cvt. Pfd. 5/8/07 764,407 0.87 508,624 TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		8/30/05	2.763.495	0.87	1.840.007	
TherOx, Inc. Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0						
Series H Cvt. Pfd. 9/11/00 3,002,748 6.38 416,085 Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		2.3,07	, ,	2.07	, - - .	
Series I Cvt. Pfd. 7/8/05 579,958 6.38 953,612 Warrants (expiration 1/26/10) 1/26/05 0 0.00 0		9/11/00	3,002,748	6.38	416,085	
Warrants (expiration 1/26/10) 1/26/05 0 0.00 0						

	Acquisition						
Security (g)	Date		Cost	per Unit		per Unit Valu	
Xoft, Inc.							
Series D Cvt. Pfd.	3/23/07	\$	2,958,518	\$	3.34	\$	3,079,063
Series E Cvt. Pfd.	6/20/08		592,532		3.34		590,001
Zyomyx, Inc.							
Series A New Cvt. Pfd.	1/12/04		299,700		0.10		30,000
Series B New Cvt. Pfd.	2/19/99, 1/12/04		468		0.10		30
New Restricted Common	2/19/99 - 7/22/04		3,602,065		0.01		3,000
		\$	65,359,781			\$	42,395,741

⁽g) See Schedule of Investments and corresponding footnotes for more information on each issuer.

Federal Income Tax Cost At December 31, 2008, the total cost of securities for Federal income tax purposes was \$370,178,755. The net unrealized loss on securities held by the Fund was \$38,398,891, including gross unrealized gain of \$42,181,103 and gross unrealized loss of \$80,579,994.

Affiliate Transactions An affiliate issuer is a company in which the Fund holds 5% or more of the voting securities. Transactions with such companies during the three months ended December 31, 2008 were as follows:

Issuer	Value on October 1, 2008	Purchases	Sales	In	come	Value on December 31, 2008
Agilix Corporation	\$ 141,809	\$	\$	\$	\$	141,809
CardioKinetix, Inc.	2,359,999					2,359,999
Concentric Medical, Inc.	10,192,176	652,013				7,932,139
CytoLogix Corporation (a)	802,074		713,080			
Eleme Medical, Inc.	3,245,001					2,596,001
Medwave, Inc.						415
PHT Corporation	5,255,869					5,255,869
-	\$ 21,996,928	\$ 652,013	\$ 713,080	\$	\$	18,286,232

⁽a) As of December 31, 2008 Cytologix Corporation is no longer an affiliate.

⁽h) The carrying value per unit of unrestricted common units of Antisoma Plc was \$0.46 on June 11, 2008, the date of the purchase agreement and date an enforceable right to acquire the restricted units was obtained.

Item 2. Controls and Procedures.

- (a.) The registrant s principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant s disclosure controls and procedures as conducted within 90 days of the filing date of this report, that these disclosure controls and procedures are adequately designed and are operating effectively to ensure that information required to be disclosed by the registrant on Form N-Q is (i) accumulated and communicated to the investment company s management, including its certifying officers, to allow timely decisions regarding required disclosure; and (ii) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission s rules and forms.
- (b.) There were no changes in the registrant s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act that occurred during the registrant s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting.

Item 3. Exhibits.

Separate certifications for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)). Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) H&Q Healthcare Investors

By (Signature and Title) /s/ Daniel Omstead

Daniel Omstead, President

Date 3/2/09

Pursuant to the requirements of the Securities and Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title) /s/ Carolyn Haley

Carolyn Haley, Treasurer

Date 3/2/09